SAVR always better for younger AS? 'Durability data up to 10-years greenlights TAVR for patients between 65-70'

Long-term valve durability becomes crucial for younger AS populations; intermediate-term data strengthens case for TAVR in select patients under 70 years

Data on TAVR-related stroke 'not enough, hard to justify routine EPD use except in BAV, ViVs,'

David J. Cohen, MD says field 'just not that good' at predicting TAVR-related stroke and its effects, but EPDs help patients with bicuspid valves, ViV procedures for now

Not just alternative to SAVR: 'TAVR has become standard of treatment for severe, symptomatic AS'

AMC Heart Institute's Chairman Seung-jung Park, MD, PhD says 'For Tissue Valves, SAVR is Alternative to TAVR' in Severe, Symptomatic AS Patients Over 65 Years

Promising new TAVR techniques, valves to realize ideal of '1 procedure, 1 valve' for life

Eberhard Grube, MD Addresses THV Newcomers, Caveats in Evolving Field of TAVR at AP VALVES & SH 2022

Celebrating 2 decades of TAVI: How 1 inventor, pioneer pushed heart history forward

Renowned French physician, interventional cardiologist Alain G. Cribier recognizes advancements, achievements of 20-year TAVI journey at AP VALVES & SH 2022